These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20205998)

  • 1. [Therapeutic drug monitoring of oxcarbazepine].
    Bouquié R; Dailly E; Bentué-Ferrer D;
    Therapie; 2010; 65(1):61-5. PubMed ID: 20205998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Bouquié R; Dailly E; Bentué-Ferrer D;
    Therapie; 2010; 65(1):61-5. PubMed ID: 27392926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of oxcarbazepine.
    May TW; Korn-Merker E; Rambeck B
    Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
    Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
    Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
    Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review.
    Bring P; Ensom MH
    Clin Pharmacokinet; 2008; 47(12):767-78. PubMed ID: 19026033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
    Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
    Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
    Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
    Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
    Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
    Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic drug monitoring of zonisamide].
    Verdier MC; Bentué-Ferrer D; Tribut O;
    Therapie; 2010; 65(1):29-34. PubMed ID: 20205992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Johannessen SI; Tomson T
    Clin Pharmacokinet; 2006; 45(11):1061-75. PubMed ID: 17048972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
    Yu Y; Zhang Q; Xu W; Lv C; Hao G
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
    Sattler A; Schaefer M; May TW
    Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
    Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
    Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
    Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
    Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic drug monitoring of vigabatrin].
    Bentué-Ferrer D; Tribut O; Verdier MC;
    Therapie; 2010; 65(1):23-7. PubMed ID: 20205991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
    Viola MS; Bercellini MA; Saidón P; Rubio MC
    Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
    Baruzzi A; Albani F; Riva R
    Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.
    Grant SM; Faulds D
    Drugs; 1992 Jun; 43(6):873-88. PubMed ID: 1379159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
    Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.